2024-11-20 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Report

**1. Performance vs. S&P 500 (VOO):**

Vertex Pharmaceuticals Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines.

The cumulative return of VRTX (164.9%) significantly outperforms the S&P 500 (VOO) cumulative return (125.6%) by 39.3 percentage points.  The relative outperformance, considering historical volatility, is at the 66.57th percentile, indicating a strong performance relative to its historical range compared to the S&P 500.

**Alpha/Beta Analysis:**  The provided data shows VRTX consistently exhibits a beta greater than 1 (except for the most recent period), suggesting higher volatility than the market.  Alpha is positive in most periods, indicating outperformance compared to the market's risk-adjusted return. However, this varied considerably over the years, highlighting the cyclical nature of performance.

| Year       | CAGR  | MDD   | Alpha | Beta  | Cap(B) |
|------------|-------|-------|-------|-------|--------|
| 2015-2017  | 21.8% | 32.2% | -16.6%| 1.6   | 38.6   |
| 2016-2018  | 34.8% | 31.5% | 2.5%  | 1.5   | 42.7   |
| 2017-2019  | 192.4%| 19.1% | 140.7%| 1.2   | 56.4   |
| 2018-2020  | 54.6% | 30.4% | 7.2%  | 0.9   | 60.9   |
| 2019-2021  | 33.8% | 34.7% | -66.2%| 0.8   | 56.5   |
| 2020-2022  | 31.6% | 34.7% | 8.0%  | 0.7   | 74.4   |
| 2021-2023  | 77.3% | 21.3% | 42.4% | 0.6   | 104.8  |
| 2022-2024  | 101.3%| 18.8% | 72.4% | 0.6   | 120.3  |


**2. Recent Price Movement:**

* **Closing Price:** $448.01
* **5-Day Moving Average:** $471.86
* **20-Day Moving Average:** $481.25
* **60-Day Moving Average:** $476.41

The current price is below all three moving averages, suggesting a potential downward trend in the short term.

**3. Technical Indicators and Expected Return:**

* **RSI (40.63):**  Approaching oversold territory (below 30), suggesting potential buying opportunities but not a definitive signal.
* **PPO (-0.93):** Negative value indicates bearish momentum.
* **Relative Strength Change (20-day):** -11.63% indicates a recent downward trend.
* **Expected Return (2+ years):** 17.79% above the S&P 500.  This is a long-term projection and subject to significant market risk.  The current price of $448.01 is not explicitly stated as a significantly high or low value given the context.

**4. Recent Financial Performance:**

The provided EPS data shows significant volatility, with a substantial negative EPS in August 2024. This needs further investigation to understand the underlying cause. Revenue remains relatively stable.  The most recent earnings report needs further context, including analyst expectations for a complete analysis.

| Date       | EPS      | Revenue    |
|------------|----------|------------|
| 2024-11-05 | 4.05     | $2.77 B    |
| 2024-08-02 | -13.92   | $2.65 B    |
| 2024-05-07 | 4.26     | $2.69 B    |
| 2023-11-07 | 4.01     | $2.48 B    |
| 2024-11-05 | 4.01     | $2.48 B    | *(Duplicate Entry)*


**5. Financial Information (Revenue and Profitability):**

The high profit margins are positive, although there's some quarter-to-quarter fluctuation.  ROE shows significant variability, highlighting the inherent risk in the biotech sector. Further analysis is required to determine the drivers of this volatility.

| Quarter     | Revenue   | Profit Margin | Equity    | ROE      |
|-------------|-----------|---------------|-----------|----------|
| 2024-09-30  | $2.77B    | 85.84%        | $15.63B  | 6.69%    |
| 2024-06-30  | $2.65B    | 85.94%        | $14.77B  | -24.32%  |
| 2024-03-31  | $2.69B    | 87.27%        | $18.55B  | 5.93%    |
| 2023-12-31  | $2.52B    | 85.38%        | $17.58B  | 5.51%    |
| 2023-09-30  | $2.48B    | 87.17%        | $16.51B  | 6.27%    |


**6. News and Recent Issues:**

* *(This section requires access to real-time news sources like Shacknews and Finbold.  Please provide recent news articles for a complete analysis.)*  A search for recent earnings news and analyst opinions on VRTX should be conducted for this section.  The provided data does not include this information.


**7. Overall Analysis:**

VRTX has shown strong long-term performance, significantly outperforming the S&P 500. However, its short-term performance is weaker, showing recent price decline and bearish technical indicators.  The significant volatility in EPS and ROE underscores the inherent risk in the biotechnology sector.  Further analysis of the recent earnings report, including comparison to analyst expectations, is crucial for a complete assessment.  The long-term expected return is positive, but investors should be prepared for significant price fluctuations.  A comprehensive review of recent news and analyst opinions is essential before making any investment decisions.


**8. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Always conduct thorough due diligence and consult with a financial advisor before making any investment decisions.
